RT Journal Article
SR Electronic
T1 Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coroners’ case reports to prevent future deaths
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.28.21256272
DO 10.1101/2021.04.28.21256272
A1 Ali Anis
A1 Carl Heneghan
A1 Jeffrey K. Aronson
A1 Nicholas J. DeVito
A1 Georgia C. Richards
YR 2021
UL http://medrxiv.org/content/early/2021/04/30/2021.04.28.21256272.abstract
AB Background The global burden of cardiovascular disease (CVD) is forecast to increase, and anticoagulants will remain important medicines for its management. Coroners’ Prevention of Future Death reports (PFDs) provide valuable insights that may enable safer and more effective use of these agents.Objective To identify CVD-related PFD reports highlighting the use or lack of anticoagulants as having caused or contributed to deaths.Methods We conducted a retrospective observational study of coronial case reports in England and Wales between 2013 and 2019. We screened 3037 PFDs for inclusion and used content analysis to assess concerns raised by coroners and who responded to them.Results We identified 113 CVD-related PFDs (113 deaths) involving anticoagulants. Warfarin (36%), enoxaparin (11%), and rivaroxaban (11%) were the most common anticoagulants reported. In 14 cases, the coroner mentioned that the administration of an anticoagulant may have prevented the death. Concerns most frequently raised by coroners included poor systems (31%), poor communication (25%), and failures to keep accurate medical records (25%). These concerns were most often directed to NHS trusts (29%), hospitals (10%), and general practices (8%), but had national importance. Nearly two-thirds (60%) of PFDs had not received responses from such organisations, which are mandatory under regulation 28 of the Coroners’ (Investigations) Regulations 2013.Conclusions We created a tool (https://preventabledeathstracker.net/) that bring together coroner reports to identify important lessons related to preventable deaths. Here we examined instances of premature deaths from CVD involving anticoagulants. National organisations, healthcare professionals, and prescribers should take actions to address these concerns, to improve the use of anticoagulants in patients with CVD.What is already known?A previous assessment of 500 PFDs identified anticoagulants as the class of drugs most often involved in fatal medication errors.What does this study add?We used innovative methods to automatically collect all available PFDs, in order to identify deaths from cardiovascular disease when the use of or lack of anticoagulants caused or contributed to the death. We found that communication, following protocols, education and training, access to resources, and safety issues were raised as concerns by coroners. Despite having national relevance, most CVD-anticoagulant PFDs were sent locally to NHS Trusts, hospitals, and general practices.How might this impact on clinical practice?Local dissemination and poor responses to PFDs limits the ability of lessons to be learnt and actions to be implemented to reduce harms and prevent premature deaths from cardiovascular disease involving anticoagulants. The concerns highlighted by coroners should be addressed by national organisations to improve safety and management of patients with cardiovascular disease.Competing Interest StatementAA has no competing interest to disclose. CH is a National Institute for Health Research (NIHR) Senior Investigator and has received expenses and fees for his media work, received expenses from the World Health Organisation (WHO), Food and Drug Administration (FDA), and holds grant funding from the NIHR School for Primary Care Research (SPCR), and the NIHR SPCR Evidence Synthesis Working Group [Project 380], the NIHR BRC Oxford and the WHO. On occasion, CH receives expenses for teaching EBM and is also paid for his GP work in NHS out of hours (contract with Oxford Health NHS Foundation Trust). CH is the Director of the CEBM. JKA has published articles and edited textbooks on adverse drug reactions and interactions and has often given medicolegal advice, including appearances as an expert witness in coroners' courts, dealing with the adverse effects of drugs. NJD has no conflicts related to the submitted work. Outside the submitted work, he declares a doctoral studentship from the Naji Foundation, grant funding from the Fetzer Franklin Memorial Fund, and employment on grants from the Laura and John Arnold Foundation, The Good Thinking Society, and the German Federal Ministry of Education and Research (BMBF). GCR was financially supported by the NIHR SPCR, the Naji Foundation, and the Rotary Foundation to study for a Doctor of Philosophy (2017-2020) but no longer has any financial COIs. GCR is an Associate Editor of BMJ Evidence Based Medicine. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.Clinical Trialhttps://osf.io/rvw43Clinical Protocols https://osf.io/rvw43 Funding StatementNo funding was obtained to undertake this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As the case reports are publicly available on the Judiciary website, approval from an ethics committee was not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesStudy materials, protocol, data, and statistical code are openly available on the OSF (https://osf.io/qkfjp/) and GitHub (https://github.com/georgiarichards/CVD_anticoags) https://osf.io/qkfjp/ https://github.com/georgiarichards/CVD_anticoags